A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer

NCT07746713 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: JNJ-98768111

Sponsor

Janssen Research & Development, LLC